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Abstract
Since the late 1990s corneal crosslinking (CXL) has been proposed as a new possibility to stop progression of
keratoconus or secondary corneal ectasia, with the promising aim to prevent progressive visual loss due to the
evolution of the pathology and to delay or avoid invasive surgical procedures such as corneal transplantation. The
possibility of strengthening corneal tissue by means of a photochemical reaction of corneal collagen by the
combined action of Riboflavin and ultraviolet A irradiation (UVA), radically modified the conservative management
of progressive corneal ectasia. This is a review of the state of the art of CXL, reporting basic and clinical evidence.
The paper describes basic principles, advantages and limits of different CXL techniques and possible future
evolution of the procedure.
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Introduction
Corneal ectasia is a progressive corneal thinning associ-
ated with alterations of stromal collagen matrix resulting
in irregular protrusion of the cornea. Primary forms in-
clude keratoconus, pellucid marginal degeneration and
keratoglobus, while secondary forms are mainly related
to refractive surgery [1].
Many studies on keratoconus epidemiology from differ-
ent countries reported an incidence of 1.3 to 22.3 per 100
000 and a prevalence of 0.4 to 86 cases per 100 000 [2].
The incidence of corneal ectasia after refractive surgery is
still unknown, but it has been estimated to be 0.04–0.6 %
after laser in situ keratomileusis(LASIK) [3–5].
Post LASIK ectasia represents about 96 % of all sec-
ondary ectasias after refractive surgery, while 4 % are re-
lated to photorefractive keratectomy (PRK) surgery [6].
Keratoconus generally starts during the second decade
of life with a variable rate of progression of corneal
steepening that continues until the fourth decade, when
the corneal shape generally becomes stable [7].
A conservative approach in the management of kera-
tectasia initially involves spectacles and subsequently,
contact lenses.
However, surgical intervention can be necessary when
patients are contact lens intolerant or cannot achieve ad-
equate vision correction. In patients with contact lens
intolerance or poor visual recovery with contact lens
use, implantation of intracorneal rings (ICRS) may im-
prove the regularity of the corneal curvature, improving
contact lens fitting and visual rehabilitation [8].
Alternatively, in advanced stages or in presence of central
corneal scarring, corneal transplantation may represent the
only viable treatment option [1]. In these cases the pre-
ferred procedure is deep anterior lamellar keratoplasty
(DALK) or, alternatively, penetrating keratoplasty (PK).
Until recently, in the “pre-CXL era”, all of the treatment
options for corneal ectatic diseases were aimed at only
overcoming refractive limitations and not to impeding the
underlying physiopathology [9].
Corneal crosslinking has grown from an interesting
concept to its introduction in clinical practice in the late
1990s when it radically modified conservative manage-
ment of progressive corneal ectasia with the possibility
of strengthening corneal tissue [10].
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Basic principles of corneal crosslinking
The primary aim of corneal crosslinking is to stop the
progression of corneal ectasia. To obtain a strengthening
of corneal tissue, the use of riboflavin is combined with
ultraviolet A irradiation (UVA). Riboflavin plays the role
of a photosensitizer in the photopolymerization process
and when combined with UVA irradiation, increases the
formation of intrafibrillar and interfibrillar carbonyl-based
collagen covalent bonds through a molecular process that
has still not been completely elucidated [1].
It was shown that during the early aerobic phase of
the process of crosslinking, riboflavin molecules are excited
to a single or triplet state and stromal proteins undergo a
photosensitized oxidation via interaction with reactive oxy-
gen species [11]. During the second anaerobic phase, when
oxygen is depleted, corneal stroma interacts with reactive
species of radical ions. This photochemical reaction results
in an increase of corneal rigidity, of collagen fiber thickness
and of resistance to enzymatic degradation, with conse-
quent decrease of stromal swelling and permeability max-
imally, above all in the anterior stroma [12].
Basic research results
Currently, the photochemically induced effect of CXL in
the cornea cannot be evidenced directly by staining
methods or microscopic techniques. However, CXL in-
duces several changes to collagen-containing tissue,
from which indirect signs of the cross-linking effect can
be deduced [9]. In fact, stress–strain measurements per-
formed on human and porcine corneas documented an
increased corneal rigidity after CXL treatment. The firm-
ing effect seems to be more evident in corneas with
higher collagen content and in older tissue [13, 14].
Moreover, it has been reported that porcine crosslinked
corneas showed a reduced tendency to swelling and
hydration when compared to untreated controls [15]. Ex
vivo studies on corneas of humans and rabbits indicated
an increase of collagen fibers thickness after CXL treat-
ment [16, 17]. Results of basic research studies showed
that CXL procedure improve the corneal resistance to
degradation processes mediated by pepsin, trypsin and
collagenase with lengthening of the turnover time of the
collagen [18].
Indications for CXL
Not every cornea with keratoconus needs to undergo
crosslinking. The main aim of CXL is to stop the pro-
gression of corneal ectasia, consequently the best candi-
dates for this treatment are patients suffering from
primary or post refractive surgery ectasia with docu-
mented progression of the disease. Although the criteria
to classify ectasia as progressive have not been defined,
changes in refraction, uncorrected visual acuity (UCVA),
best-corrected visual acuity (BCVA), and topographical
parameters are to be included. To date, published clin-
ical studies indicated that CXL was used in cases of pro-
gression over a well-defined time period. In many
reports, progression was defined as an increase in Kmax
of 1 diopter (D) in 1 year, or a change in either myopia
and/or astigmatism ≥3 D in 6 months, a mean central
K-reading change ≥1.5 D observed in three consecutive
topographies in 6 months, or a mean central corneal
thickness decrease ≥5 % in three consecutive tomogra-
phies in the previous 6 months. Contraindications to
undergoing standard CXL treatment are the presence of
corneal thickness of less than 400 microns, prior her-
petic infection, severe cornea scarring or opacification,
history of poor epithelial wound healing, severe ocular
surface disease, history of immune disorders, and preg-
nancy/breast-feeding [19–21].
Standard procedure and clinical results
The standard Dresden protocol, as initially described by
Wollensask et al. includes initial epithelial removal, the
application of 0.1 % riboflavin solution for 30 min
followed by 30 min of UVA irradiation with a wavelength
of 370 nm and power of 3 mW/cm2 (5.4 J/cm2) [22].
A list of publications reporting the clinical results of
traditional CXL procedures is shown in Table 1 [23–65].
In the last few years, several prospective and retrospective
studies with a considerable follow-up period documented
the effectiveness of the standard procedure in halting the
progression of primary and secondary corneal ectasia, and
in many cases, with an improvement of visual perform-
ance and topographical indexes.
Most of the reports about clinical outcomes of stand-
ard epi-off CXL are prospective or retrospective case
series. In the follow-up after treatment, the main param-
eters evaluated are the maximal keratometry (Kmax) and
the best corrected visual acuity (BCVA). The follow-up
periods ranged between one and six years. All authors
reported stabilization or flattening of corneal keratome-
try and stabilization or improvement of visual acuity
after standard epi-off procedure.
The small number of randomized controlled trials may
affect the interpretation of these results. However, the
results reported by Wittig-Silva et al. (2015) of 100 eyes
with a three-year follow-up constitute an important
milestone that confirms the effectiveness of epi-off tech-
nique in stabilizing keratoconus progression [35].
Limits and complications of standard procedure
Treatment failure
Treatment failure that occurs in 8.1–33.3 % of the cases
is usually defined as continued progression with an
increase in maximum K readings of 1.0 D over the
preoperative value [66].
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Table 1 Outcomes reported in literature for standard epi-off CXL procedures (2010–2015)




Lang S et al. (2015) [23] 3 years D - RCS 29 Keratoconus
Poli M et al. (2015) [24] 6 years S I PCS 36 Ectasia
Di Bernardo M et al. (2015) [25] 2 years D I PCS 57 Keratoconus
McAnena L et al. (2015) [26] 3 years S I RCS 25 Pediatric Keratoconus
Sedaghat M et al. (2015) [27] 1 year S D I PCS 97 Keratoconus
Khan WA (2015) [28] 3 years D I PCS 71 Keratoconus
Yildirim A et al. (2014) [29] 42 months D I RCS 20 Post LASIK ectasia
Kymionis GD et al. (2014) [30] 5 years D I PCS 25 Keratoconus
Kumar Kodavoor S (2014) [31] 1 year S I RCS 24 Pediatric Keratoconus
Viswanathan D et al. (2014) [32] 20 months D S PCS 25 Pediatric Keratoconus
Goldich I et al. (2014) [33] 3 years S S PCS 17 Keratoconus
Steinberg J et al. (2014) [34] 2 years D I PCS 20 Keratoconus
Wittig-Silva C et al. (2014) [35] 3 years D I RCT 100 Keratoconus
Elbaz U et al. (2014) [36] 1 year S S PCS 9 Radial Keratotomy
Ghanem RC et al. (2014) [37] 2 years D I PCS 42 Keratoconus
Toprak I et al. (2013) [38] 1 year D I RCS 59 Keratoconus
Hashemi H et al. (2013) [39] 5 years D I PCS 40 Keratoconus
Richoz O et al. (2013) [40] 2 years D I RCS 26 Post LASIK/PRK ectasia
Ivarsen A et al. (2013) [41] 22 months D S RCS 22 Keratoconus
Legare ME et al. (2013) [42] 2 years S S RCS 39 Keratoconus
O’Brart (2013) [43] 4-6 years S S RCS 30 Keratoconus
Arora R et al. (2012) [44] 12 months I PCS 15 Pediatric Keratoconus
Chatzis N et al. (2012) [45] 3 years S I RCS 59 Pediatric Keratoconus
Vinciguerra R et al. (2013) [46] 4 years D I RCS 400 Keratoconus
Viswanathan D et al. (2013) [47] 14 months D I PIS 76 Keratoconus
Poli M. et al. (2013) [48] 3 years S S PC 55 primary and secondary
ectasia
Lamy R et al. (2013) [49] 2 years D I PC 68 Keratoconus
Kranitz K et al. (2012) [50] 1 year D I PC 40 Keratoconus
Guber I et al. (2013) [51] 1 year S I PCS 33 Keratoconus
Vinciguerra P et al. (2012) [52] 2 years K1 S/
K2 D
I PCS 40 Pediatric Keratoconus
Caporossi A et al. (2012) [53] 3 years D I PCS 152 Pediatric Keratoconus
Goldich I et al. (2012) [54] 2 years D I PCS 14 Keratoconus
Asri D et al. (2011) [55] 1 year S S PCS 142 Keratoconus
Fuentes-Paez G et al. (2012) [56] 6 months S I PCS 7 Ectassia post RK
Kymionis GD et al. (2012) [57] 1 year S S PCS 14 Keratoconus
Koller T et al. (2011) [58] 1 year D S PCS 151 Keratoconus
Greenstain SA et al. (2011) [59] 1 year D S RCT 71 Primary and secondary
ectasia
Raiskup F et al. (2011) [60] 1 year S S RCS 32 Keratoconus
Hersh P et al. (2011) [61] 1 year S I RCT 71 Keratoconus
Salgado JP et al. (2011) [62] 1 year S S PCS 22 Post LASIK ectasia
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Poli et al. recently reported a failure rate of 11 % during
a follow-up period of six years. Keratoconus worsening
was considered if patients presented an increase of more
than 0.1 in logMAR uncorrected and best corrected visual
acuity and/or an increase of keratometric values by more
than 0.75 D during the follow-up [24].
After standard CXL procedure, corneal haze is a rela-
tively common complication reported by 10-90 % of
patients. However, to date the etiology and the natural
course of clinical corneal haze after epi-off procedure
has not been clearly defined [67, 68]. In vivo confocal
microscopy showed an increased stromal reflectivity
associated to edema and keratocyte activation mainly
evident 3–6 months after treatment, while in the late
postoperative period, anterior and intermediate stromal
layers showed a reduction of cellular density and fibrosis
of extracellular matrix [69].
Several cases of infective keratitis following CXL treat-
ment have been described including bacterial, protozoal,
herpetic, and fungal keratitis [70].
The rare serious adverse events following traditional
CXL that have been reported included diffuse lamellar
keratitis at LASIK interface, corneal melting and persist-
ent corneal edema due to endothelial failure [71–73].
Introduction of epi-on technique
The diffusion process of riboflavin in the stroma is limited
by corneal epithelial tight junctions [74, 75], but epithelial
debridement is considered the cause of the most im-
portant complications after CXL treatment such as
intraoperative and postoperative pain, infective keratitis
and abnormal wound-healing response [76, 77]. Riboflavin
penetration through the epithelium can be increased by
different strategies such as changing the physicochemical
properties of the riboflavin molecule by adding chemical
enhancers in the riboflavin formulation [78] or performing
a mechanical disruption of corneal epithelium [79]. An in
vivo confocal microscopy study reported that by increas-
ing the duration of riboflavin application up to two hours,
the obtained depth of CXL effect is similar to that
achieved with standard epi-off technique [80].
Although the complication rate in patients treated
with transepithelial CXL was reported to be low [69], so
was the effectiveness of this technique (Table 2) [81–89].
Thus, its utility is still a matter of debate.
Iontophoresis
A novel approach to enhance riboflavin penetration is
based on iontophoresis, a non-invasive system aimed to
enhance the delivery of charged molecules into tissues
using a small electric current [90]. Riboflavin, in the for-
mulation used for iontophoresis, is negatively charged. It
has been shown that an iontophoresis imbibition lasting
five minutes achieves a sufficient riboflavin concentra-
tion in the corneal stroma for CXL treatment, with the
advantage of shortening the imbibition time while pre-
serving epithelial integrity [9].
Numerous ex vivo studies confirmed the effectiveness
of iontophoresis imbibition in obtaining an adequate
riboflavin concentration into the stroma and the induc-
tion of important biomolecular and structural modifica-
tions of corneal tissue [90–92]. Ex vivo biomechanical
studies on rabbit and human cadaveric corneas showed
that transepithelial crosslinking with iontophoresis imbi-
bition induced an increase of the biomechanical resist-
ance of human cornea comparable to that obtained with
the standard crosslinking procedure [93, 94].
Preliminary clinical results of iontophoresis assisted
corneal CXL are promising. The technique halts keratoco-
nus progression without significant complications (Table 3)
[95–97] however, longer follow-up and studies with larger
patient populations are needed to assess the real effective-
ness of this technique.
Accelerated corneal crosslinking
Accelerated CXL was introduced in clinical practice in
order to shorten the time required for a CXL procedure.
This technique is based on the Bunsen-Roscoe law of
photochemical reciprocity. That is, the same photo-
chemical effect can be achieved with reducing the irradi-
ation interval provided that the total energy level is kept
constant by a corresponding increase in irradiation in-
tensity [1]. Currently, commercially available ultrafast
devices can achieve an irradiance intensity of 43 mW/
cm2. Using this setting, a total treatment time of two mi-
nutes is required to achieve a standard Dresden protocol
energy dose of 3.4 J or a radiant exposure of 5.4 J/cm2
[1]. Several recent in vivo studies using different proto-
cols showed the procedure to be safe and effective in
stopping ectasia progression (Table 4) [98–105].
Comparative studies of the effectiveness of the different
CXL procedures are described in Table 5 [106–115].
Table 1 Outcomes reported in literature for standard epi-off CXL procedures (2010–2015) (Continued)
Caporossi A et al. (2010) [63] 4 years D I PCS 44 Keratoconus
Vinciguerra P et al. (2009) [64] 2 years D I PCS 28 Keratoconus
Vinciguerra P et al. (2010) [65] 1 year D I PCS 13 Post LASIK/PRK ectasia
S= Stabilized, D= Significantly decreased, I= Significantly improved, PCS= Prospective case series, RCS= Retrospective case series, RCT= Randomized controlled
trial, PIS= Prospective interventional study, PC= Prospective comparative
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Surgical protocols reported are very different and unlikely
comparable. Also, the follow-up periods are very limited.
Therefore, it is very difficult to deduce reliable conclu-
sions. It seems likely that transepithelial CXL, although
associated with a lower complication rate, has a lower
therapeutic effect than standard CXL and would be ideal
for patients with thin corneas, uncooperative individuals,
or those with uncertain documented progression. Ionto-
phoresis assisted CXL is a promised technique that could
obtain clinical effects similar to those obtainable with a
standard technique while maintaining the advantages of
epithelium preservation. However, while the basic re-
search results are evident, clinical outcomes are still poor.
Accelerated CXL seems to represent a valid strategy to
shorten the long treatment time, however the extreme
variability of the protocols proposed has not been
supported by adequate safety assessment. Well-designed
randomized controlled trials comparing traditional CXL
and all the alternative procedures are required in order to
establish which is the ideal protocol for obtaining the best
clinical outcomes and complication profile.
Combined treatments
CXL and photorefractive keratectomy
Keratoconus has always been considered a contraindica-
tion for PRK. However, during the last few years, the
idea of performing PRK in patients with stable keratoco-
nus has been proposed. Consequently, the possibility of
combining CXL and PRK was introduced in clinical
practice [116–120]. Several clinical reports demonstrated
stability in corneas that had undergone a combination of
CXL and PRK, either sequentially or combined. Patients
experienced improvement in spherical equivalent (SE),
defocus equivalent, uncorrected and best corrected
visual acuity, high order aberrations and Kmax with
stabilization of keratoconus progression during a follow
up period of 12–24 months [121–124].
The timing of the ablation treatment and CXL as well
as the interval between the two procedures has become
topics of discussion. It was reported that patients who
underwent both PRK and CXL procedures in the same
day obtained better clinical and topographical results
with a lower rate of corneal haze, compared to patients
treated sequentially [125]. This may be related to the un-
predictable refractive outcomes when excimer ablation is
performed on cross-linked tissue [126]. However, per-
forming both procedures concurrently in the same day
may cause an irregular healing process with the formation
of persistent stromal haze, probably related to keratocyte
activation, which permanently affects visual performance
[127, 128].
CXL and intracorneal rings
Studies reported that CXL halts keratoconus progres-
sion, but the overall results in terms of visual rehabilita-
tion were insufficient. On the other hand, intracorneal
ring segments (ICRS) produced rapid and substantial
improvements of visual parameters but do not stop
Table 2 Outcomes reported in literature for epi-on CXL procedures (2010–2015)
Author (Year) Follow-up Results Design Number of Eyes Indication
Kmax Mean Keratometry BCVA
Lensiak SP et al. (2014) [81] 6 months S S PCS 25 Keratoconous
De Bernardo M et al. (2014) [82] 6 months S I PCS 36 Keratoconus
Khairy HA et al. (2014) [83] 1 year D S PCS 32 Keratoconus
Salman AG (2013) [84] 1 year S S PC 22 Pediatric Keratoconus
Caporossi A et al. (2013) [85] 2 years W S PCS 26 Keratoconus
Buzzonetti L et al. (2012) [86] 18 months W I PCS 13 Pediatric Keratoconus
Spadea L et al. (2012) [87] 1 year D I PCS 16 Keratoconus
Filippello M et al. (2012) [88] 18 months D I PC 20 Keratoconus
Leccisotti A et al. (2011) [89] 1 year S I RCT 51 Keratoconus
S= Stabilized, D= Significantly decreased, I= Significantly improved, W= worsened, PCS= Prospective case series, RCT= Randomized controlled trial, PC=
Prospective comparative
Table 3 Outcomes reported in literature for iontophoresis assisted corneal CXL procedures (2014–2015)
Author (Year) Follow-up Results Type Number of Eyes Indication
Kmax BCVA
Buzzonetti L et al. (2015) [95] 15 months S I PCS 14 Pediatric Keratoconus
Bikbova G et al. (2014) [96] 1 year D I PCS 22 Keratoconus
Vinciguerra P et al. (2014) [97] 1 year S I PCS 20 Keratoconus
S= Stabilized, D= Significantly decreased, I= Significantly improved, PCS= Prospective case series
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progression. Theoretically, a combination of these two
procedures can produce better results [1].
Several studies reported concordant results confirming
that combining CXL and ICRS implantation improved
uncorrected and best corrected visual acuity, refraction,
and keratometry during variable follow-up periods (7–12
months) [129–131]. One study reported no difference in
topographical or visual outcome after ICRS or ICRS
combined with CXL. Thus, the real effect of the
combined treatment to the keratoconus progression is
still unclear [132].
Moreover, it was reported that after one or both ring
explantations, the refractive effects may be stable or
reversible while the topographic changes seems to be
maintained [133]. Therefore, while collagen crosslinking
can be performed before, in conjunction with, or after
ICRS implantation, the ideal method for combining
these two treatments is still undefined [1].
Table 4 Outcomes reported in literature for accelerated corneal CXL procedures (2014–2015)
Author (Year) Tecnique Follow-up Results Type Number of Eyes Indication
Kmax K1/K2 BCVA
Chan TC et al. (2015) [98] Accelerated 1 year S S PCS 25 Keratoconus
Ozgurhan EB et al. (2015) [99] Accelerated 1 year R I PCS 34 Keratoconus
Marino GK et al. (2015) [100] Accelerated 2 years S S PCS 40 Post LASIK ectasia
Waszczykowska A (2015) [101] Accelerated 2 years S S PCS 16 Keratoconus
Ozgurhan EB et al. (2014) [102] Accelerated 2 years D I RCS 44 Pediatric Keratoconus
Shetty R et al. (2014) [103] Accelerated 2 years - I PCS 18 Keratoconus
Elbaz U et al. (2014) [104] Accelerated 1 year S S PCS 16 Keratoconus
Cinar Y et al. (2014) [105] Accelerated 6 months D I PCS 23 Keratoconus
S= Stabilized, D= Significantly decreased, I= Significantly improved, PCS= Prospective case series, RCS= Retrospective case series
Table 5 Outcomes reported in literature comparing different CXL procedures (2013–2015)
Author (Year) Techniques
compared




NG AL et al.
(2015) [106]
















Rossi S et al.
(2015) [108]
Standard vs TE 1 year Improvement Kmax in
standard and TE CXL
Improvement BCVA in




Standard vs accelerated 1 year Stabilization K max in
standard CXL
RCS 131 Keratoconus
Hashemian H et al.
(2014) [110]













Stojanovic A et al.
(2014) [112]
Standard vs TE 1 year Stabilization Kmax for
standard and TE CXL
Improvement BCVA in
standard and TE CXL
RCT 40 Keratoconus
Tomita M et al.
(2014) [113]







Cinar Y et al.
(2014) [114]







Magli A et al.
(2013) [115]
Standard vs TE 1 year Improvement K max in
standard and TE CXL
Improvement BCVA in
standard and TE CXL
PC 37 Keratoconus
CIS= Comparative Interventional Study, PR= Prospective randomized, RCS= Retrospective case series, RCT= Randomized controlled trial, PC= Prospective comparative
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Alternative uses of corneal crosslinking
Infections
Crosslinking has an antimicrobial effect inherent to UV
light interacting with riboflavin as the chromophore. In
fact, UV irradiation is used as an antimicrobial proced-
ure for disinfecting water, surfaces and air. It damages
both the DNA and RNA of pathogens including bacteria
and viruses, and renders them inactive [134].
Additionally, the photoactivated riboflavin seems to
produce an antimicrobial effect. In fact, the use of ribofla-
vin as a photosensitizer to inactivate pathogens in plasma,
platelet, and red cell products has been described [135].
Due to its nucleic acid specificity and its limited ten-
dency toward indiscriminate oxidation, riboflavin was
hypothesized as a photosensitizer for the inactivation of
pathogens in infective keratitis. It was reported that
riboflavin activated by UVA showed an antimicrobial
effect on agar plates inoculated with Pseudomonas aeru-
ginosa, Staphylococcus aureus, Staphylococcus epidermi-
dis, Streptococcus pneumoniae, and Candida albicans.
The inhibition of microbial growth was significantly
higher in plates treated with UVA activated riboflavin
than in those treated with UVA light alone. However,
riboflavin alone did not show any significant bactericidal
effect [136].
The first reported use of CXL in infective keratitis was
in 2008, when Iseli at al. reported healing 4 out of 5
cases of mycobacterial and fungal corneal melting unre-
sponsive to conventional therapy, treated with the standard
Dresden protocol [137]. In 2013, Alio et al. in a systematic
review and meta-analysis reported similar results [138]. In
2014, Said et al. reported a large prospective clinical trial
on infective keratitis comparing 21 eyes treated with CXL
in addition to antimicrobial therapy in 19 eyes that re-
ceived only antimicrobial therapy. They did not find a sig-
nificant difference between both groups in terms of healing
time and final visual acuity. Three patients treated with
antimicrobial therapy alone experienced corneal perfor-
ation and one an infection relapse while no significant
complications occurred in CXL group. The authors con-
clude that CXL could serve as a valuable adjuvant therapy
and may reduce or avoid severe complications preventing
the need for emergency keratoplasty [139].
Pseudophakic bullous keratopathy
In case of corneal edema due to endothelial failure, it
has been shown that CXL effect increases corneal resist-
ance to swelling processes. In fact CXL increases the in-
terfiber collagen connections and it’s difficult for stromal
fluid to separate collagen lamellae and create a potential
space for edema accumulation . Therefore, the use of
corneal CXL was proposed as an alternative approach
for the management of pseudophakic bullous keratopa-
thy (PBK) with the aim to reduce ocular discomfort,
improve visual acuity, and delay the need for kerato-
plasty [140].
Clinical studies evaluating the effectiveness of corneal
CXL in the treatment of PBK reported a significant im-
provement in corneal transparency, corneal thickness,
and ocular pain one month postoperatively. However,
CXL did not seem to have a long-lasting effect over six
months in decreasing pain and maintaining corneal
transparency [141, 142].
Conclusions
At the light of this review we can conclude that there is
still much to understand about the real modification of
corneal collagen structure after the photochemical CXL
reaction. Moreover the constant aim of basic and clinical
research today is to identify the best strategies and com-
bination of imbibition and irradiation that can lead to
the better clinical efficacy together with the maximum
safety of the treatment.
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